Bausch Health Companies Inc.BHCEarnings & Financial Report
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Revenue
$2.3B
Gross Profit
N/A
Operating Profit
$276.0M
Net Profit
$-58.0M
Gross Margin
N/A
Operating Margin
12.2%
Net Margin
-2.6%
YoY Growth
4.9%
EPS
$-0.16
Bausch Health Companies Inc. Q1 FY2025 Financial Summary
Bausch Health Companies Inc. reported revenue of $2.3B (up 4.9% YoY) for Q1 FY2025, with a net profit of $-58.0M (up 9.4% YoY) (-2.6% margin).
Key Financial Metrics
| Total Revenue | $2.3B |
|---|---|
| Net Profit | $-58.0M |
| Gross Margin | N/A |
| Operating Margin | 12.2% |
| Report Period | Q1 FY2025 |
Revenue Breakdown
Bausch Health Companies Inc. Q1 FY2025 revenue of $2.3B breaks down across 6 segments, led by Bausch Lomb at $1.1B (50.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Bausch Lomb | $1.1B | 50.3% |
| Salix Segment | $542.0M | 24.0% |
| International Rx | $262.0M | 11.6% |
| Diversified Segment | $205.0M | 9.1% |
| Solta Medical Segment | $113.0M | 5.0% |
| Price Appreciation Credit | $2.0M | 0.1% |
Bausch Health Companies Inc. Revenue by Segment — Quarterly Trend
Bausch Health Companies Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Bausch Lomb and Salix Segment) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Bausch Lomb | $1.4B | $1.3B | — | $1.1B |
| Salix Segment | $693.0M | $716.0M | — | $542.0M |
| International Rx | $306.0M | $286.0M | — | $262.0M |
| Diversified Segment | $255.0M | $258.0M | — | $205.0M |
| Solta Medical Segment | $137.0M | $140.0M | — | $113.0M |
Bausch Health Companies Inc. Annual Revenue by Year
Bausch Health Companies Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $10.3B).
| Year | Annual Revenue |
|---|---|
| 2025 | $10.3B |
| 2024 | $9.6B |
| 2023 | $8.8B |
| 2022 | $8.1B |
Bausch Health Companies Inc. Quarterly Revenue & Net Profit History
Bausch Health Companies Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $2.8B | +9.3% | $-103.0M | -3.7% |
| Q3 FY2025 | $2.7B | +6.8% | $179.0M | 6.7% |
| Q2 FY2025 | $2.5B | +5.3% | $148.0M | 5.8% |
| Q1 FY2025 | $2.3B | +4.9% | $-58.0M | -2.6% |
| Q4 FY2024 | $2.6B | +6.3% | $98.0M | 3.8% |
| Q3 FY2024 | $2.5B | +12.2% | $-85.0M | -3.4% |
| Q2 FY2024 | $2.4B | +10.9% | $10.0M | 0.4% |
| Q1 FY2024 | $2.2B | +10.8% | $-64.0M | -3.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.15B | $2.40B | $2.51B | $2.56B | $2.26B | $2.53B | $2.68B | $2.80B |
| YoY Growth | 10.8% | 10.9% | 12.2% | 6.3% | 4.9% | 5.3% | 6.8% | 9.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $26.91B | $26.50B | $26.54B | $26.52B | $26.42B | $27.27B | $26.82B | $26.37B |
| Liabilities | $27.09B | $26.72B | $26.78B | $26.84B | $26.66B | $27.12B | $26.47B | $25.99B |
| Equity | $-1.11B | $-1.18B | $-1.17B | $-1.28B | $-1.18B | $-764.0M | $-565.0M | $-554.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $211.0M | $380.0M | $405.0M | $601.0M | $211.0M | $289.0M | $405.0M | $495.0M |